Cornerstone Robotics
About
About Cornerstone Robotics
Cornerstone Robotics develops and manufactures the Sentire Endoscopic Surgical System for surgeon-controlled minimally invasive procedures. A surgeon console commands 5- and 8-millimetre wristed instruments on a patient-side robot, while high-definition three-dimensional imaging provides magnified views and tremor filtering smooths hand motion. The platform supports urology, gynaecology, thoracic and gastrointestinal procedures through small incisions.
Mechanical architecture, controls, imaging, instruments and software are developed in-house and produced through a 30,000-square-metre manufacturing facility in China. Sentire gained Chinese approval, then EU MDR and Singapore HSA certification in May 2026. Clinical work has included procedures at Portsmouth Hospitals in the United Kingdom and a Singapore installation for testing, training and workflow adaptation. Cornerstone supports adoption through regional service, clinical training and technical teams.
Products
- Sentire Surgical Robotic System
Sentire Surgical Robotic System
Supply
Supply chain relationships
- Medtronic
Outbound - Equipment - Cornerstone Robotics supplies Sentire surgical-system distribution rights for approved markets outside the United States
Source
Funding
- 2025-11-11 - Venture round - Cornerstone Robotics closes approximately US$200M financing
Cornerstone Robotics closed an oversubscribed financing round of approximately US$200 million to accelerate commercialization, technology development and global expansion. - source: en.csrbtx.com
- 2025-01-13 - Series C - $70M - Cornerstone Robotics raises more than USD 70 million Series C
Cornerstone Robotics raised more than USD 70 million in Series C financing led by EQT. - source: en.csrbtx.com
Timeline
Events
- 2026-09-01 - Partnership - Cornerstone Robotics and Medtronic sign Sentire distribution partnership
The approximately $700 million investment includes distribution rights for Sentire in select markets outside the United States where the system is approved. Medtronic plans to offer Sentire alongside its Hugo RAS surgical system. Sentire received CE Mark in May 2026 and has market approvals in China and Singapore.
Source - 2026-05-25 - Regulatory - Sentire receives European CE Mark and Singapore HSA certification
The European certification was issued under the Medical Device Regulation. Singapore Health Sciences Authority certification was obtained at the same milestone. Both certifications cover minimally invasive general, gynecological, thoracic and urological surgery and enable market access in Europe and Singapore.
Source - 2025-11-11 - Funding - Cornerstone Robotics closes approximately US$200M financing
A global strategic investor, institutional and sovereign-wealth investors, and existing shareholders participated. The company did not publicly identify the investors or a lead. Proceeds were allocated to commercialization, continued technological innovation and international market access.
Source - 2025-01-13 - Funding - Cornerstone Robotics raises more than USD 70 million Series C
EQT led the Series C of more than USD 70 million. Qiming Venture Partners, Alpha JWC Ventures, Hong Kong Innovation and Technology Venture Fund, eGarden Ventures, CTS Funds, K2VC and Long-Z Capital participated. Cornerstone allocated the financing to commercialization, product development, clinical trials, approvals and international adoption.
Source
Relations
Relationships
- Medtronic
Sentire Distribution Rights - Medtronic holds rights to distribute Cornerstone Robotics Sentire surgical system in select approved markets outside the United States.